Dec 11, 2025 19:41 JST

Source: Eisai

Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

TOKYO, Dec 11, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that it has been selected for the highest-rated “A” List in the fields of Climate Change and Water Security for 2025 by the global environmental non-profit organization CDP.(1) This marks the second consecutive year the company has been named in both categories of the CDP’s A List.

Based on Eisai’s Future Creation Strategy(2) (Sustainability Strategy), the company is committed to addressing material issues and social challenges over the mid- to long- term, with the aim of contributing to sustainable corporate growth and the sustainable development of society. In the field of environmental conservation, Eisai has identified “Business activities with consideration for the global environment” as one of our material issues. Based on the Eisai Network Companies Environmental Policy, Eisai is promoting responses to climate change and sustainable water use as environmental activities across the group.

As part of its climate change response, Eisai is working towards the realization of a decarbonized society, including obtaining approval for the SBT 1.5'C target from the Science Based Targets (SBT) Initiative in FY2023, and participating in the Japan Climate Initiative (JCI) Race to Zero Circle, which calls for achieving net zero by 2050. Through these efforts, Eisai is contributing to the reduction of greenhouse gas emissions.(3) Regarding sustainable water use, Eisai has set its mid-term target to reduce water withdrawal across the company by 7%(4) by FY2030 compared to FY2023, promoting efficient use of water resources, including recycling of laboratory wastewater and rainwater. Please refer to Eisai’s website for more detailed information about its environmental activities.

To realize the human health care (hhc) concept, conservation of the global environment is essential. Eisai is committed to empowering people to “realize their fullest lives” through initiatives addressing climate change and the promotion sustainable water use.

(1) A non-profit organization headquartered in the UK. The organization operates the world’s only independent environmental information disclosure system
(2) Please refer to Eisai Value Creation Report (https://www.eisai.com/ir/library/annual/pdf/pdf2025vcr.pdf)
(3) Please refer to the following news release for details. EISAI TO BOOST INITIATIVES ON GREENHOUSE GAS REDUCTION, AIMING TO ACHIEVE NET ZERO BY 2050 (https:/www.eisai.com/news/2024/news202412.html)
(4) Per unit of sales

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: Environment, ESG

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
 
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
December 04 2025 17:36 JST
 
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 03 2025 17:19 JST
 
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
December 02 2025 23:01 JST
 
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
November 28 2025 22:00 JST
 
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
November 26 2025 18:42 JST
 
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
November 17 2025 21:08 JST
 
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
 
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
 
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
 
More Press release >>

Latest Press Release


More Latest Release >>